Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P0DP24

UPID:
CALM2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P0DP24; P02593; P62158; P70667; P99014; Q13942; Q53S29; Q61379; Q61380; Q96HK3

BACKGROUND:
Calmodulin-2 is integral to calcium-mediated signal transduction, influencing the function of enzymes, ion channels, and other proteins. It facilitates the activation of various protein kinases and phosphatases, plays a role in cell division, and contributes to the regulation of ion channel activities. Its interaction with calcium is essential for its regulatory functions.

THERAPEUTIC SIGNIFICANCE:
The association of CALM2 mutations with Long QT Syndrome 15 highlights its critical role in cardiac health. Exploring Calmodulin-2's functions further could lead to innovative treatments for cardiac arrhythmias and other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.